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Abstract. Synthetic peptides corresponding to cDNA-
deduced amino acid sequences unique to the human
and mouse retinoic acid receptor yl (hRAR-yl and
mRAR-yl, respectively) were used to generate anti-
RAR-yl antibodies. Four mAbs were selected, which
were directed against peptides found in region Al
(Ably(Al)), region F (Ab2y(mF) and Ab4y(hF)) and
region D2 (Ab5y(D2)) . These antibodies specifically
immunoprecipitated and recognized by Western blot-
ting RAR-yl proteins in COS-1 cells transfected with
expression vectors containing the RAR-yl cDNAs.
They all reacted with both human and mouse RARyl
proteins, except Ab4y(hF) that was specific for hRAR
yl. Rabbit polyclonal antibodies, directed against a
peptide from the mRAR-yl F region were also ob-
tained (RPy(mF)) and found to be specific for mouse
R
TINoic acid (RA),' a vitamin A derivative, which is
thought to be a natural morphogen (Maden, 1982 ;
Thaller and Eichele, 1987), can act as a signaling
molecule in a number ofdevelopmental systems. The pleio-
tropic effects of RA are likely to be mediated by specific nu-
clear RA receptors (RARs) which have been discovered in
mouse and human (designated RARa, -ß, and -y) (Petko-
vich et al., 1987; Giguère et al., 1987; Brand et al., 1988 ;
Benbrook et al., 1988 ; Krust et al ., 1989; Zelent et al.,
1989). RARs belong to the steroid/thyroid hormone recep-
tor superfamily, whose members act as ligand-inducible
transcriptional enhancer factors (for reviews see Evans,
1988; Green and Chambon, 1988; Beato, 1989 and refer-
ences herein) and can be divided into six distinct regions
designated A through F (see Petkovich et al., 1987; Green
and Chambon, 1988; Brand et al ., 1988). The complexity
of RARs has been further illustrated by the finding of multi-
ple cDNA isoforms for each RAR (Krust et al., 1989; Gi-
gu6re et al., 1990; Kastner et al., 1990; Leroy et al ., 1991;
Zelent et al ., 1991). For each RAR gene (either a, ,ß, or y)
1. Abbreviations used in thispaper: NE, nuclear extracts; p.c., post-coitum;
RA, retinoic acid; RAR, retinoic acid receptor; RARE, retinoic acid re-
sponse element; NC, nitrocellulose; WCE, whole cell extracts.
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RARyl protein. Furthermore, in gel retardation/shift
assays the antibodies specifically retarded the migra-
tion of complexes obtained with a RA response ele-
ment (RARE). Antibodies raised against regions D2
and F also recognized the RARy2 isoform which
differs from RARyI only in the A region. On the
other hand, antibodies directed against the Al region
of RAR-yl (Ably(Al)) only reacted with the RARyl
protein. The antibodies characterized here allowed us
to detect the presence of mRARyl and 72 isoforms
in mouse embryos and F9 embryonal carcinoma cells
nuclear extracts. They were also used to demonstrate
that the mRARy1 protein can be phosphorylated and
that the phosphorylation occurs mainly in the NH2-
terminal A/B region.
the corresponding isoform messenger RNAs are generated
from two promoters and differential splicing ofexons encod-
ing the A region.
Specific spatial and temporal patterns ofdistribution ofthe
RAR-a, -ß, and -y transcripts have been demonstrated in
adult mouse tissues (Krust et al., 1989; Zelent et al ., 1989;
Kastner et al., 1990) and during mouse embryogenesis
(Dollé et al., 1989,1990; Ruberte et al., 1990, 1991) . In par-
ticular, the localization of RARy transcripts during embryo-
genesis as determined by in situ hybridization, suggests that
RAR-y plays an important role during early morphogenesis
and differentiation of cartilage and cornified squamous
epithelia (Dollé et al., 1989, 1990; Ruberte et al., 1990,
1991). Furthermore, the two predominant RAR-y isoforms,
RAR-yl and RAR-y2, appear to be differentially expressed
in adult tissues and during the course of embryogenesis, as
determined by Northern blot analysis (Kastner et al ., 1990).
In this paper, we describe the preparation and character-
ization ofrabbit polyclonal and mouse mAbs directed against
synthetic peptides specific to mouse and/or human RAR-y
isoforms. These antibodies specifically immunoprecipitate
and recognize by Western blotting mouse or human RARy
in cells transfected with expression vectors containing the
corresponding cDNAs. They also specifically retard the
535migration of RAR-,y/RARE (RA response element) com-
plexes in gel shift assays. Additionally, these antibodies al-
lowed us to detect the presence ofRAR--y isoforms in F9 em-
bryonal carcinoma cellsand mouse embryos, despite the low
amount of these proteins in such cells and tissues. Finally,
using our antibodies, we have been able to demonstrate that
the RAR-y protein is posttranslationally modified by phos-
phorylation.
Materials and Methods
DNA Constructs
The plasmids containing the mouse or human RAR gene coding sequences
RAR-al, RAR-ß2, and RAR-,yl (previously referred to as RAR-a0, RAR-
00, and RAR--yO, respectively), were as described (Petkovich et al ., 1987;
Brandet al., 1988; Krust et al., 1989; Zelent et al., 1989). The construction
of the isoform mRAR-y2 expression vector has been reported (Kastner et
al., 1990).
The GALA/RAR-yl(A/B) chimera was constructed by replacing the hu-
man estrogen receptor (hER) exon 7 in the vectorGALA-Exon7-F (Webster
et al., 1989) witha265-bp Xhol-Kpnl fragmentencoding aminoacids 1-89
ofmRAR-yl (A/B region). Amino acids in the linkerbetweenGALA (1-147)
and the RAR-yl A/B region are IGRPPRA. The GALA-RAR-y(EF) and
(DEF) constructs were made similarly by replacing hER exon 7 with a 782-
bp Xhol-Kpnl fragment (encoding amino acids 201-458 of mRAR-71) and
a 917-bp Xhol-Kpnl fragment (amino acids 156-458 of mRAR-yl), respec-
tively. GALA-RAR-y(EF) and (DEF) chimeras also contain the amino acids
IGRPPRA in the linker region. The mRAR-yl Xhol-Kpnl cassettes were
obtained from mRARyI clones that had been modified by two rounds of
site directed mutagenesis to introduce Xhol and KpnI restriction sites at
selected positions. Each of the three chimeric constructs encodes amino
acids 553-595 of hER (F region) as acarboxyl terminal antigenic tag against
which mAbs (AbF3) have been raised (Rochette-Egly et al., 1990).
Cell Culture and Tlransfection
COS-1 cells were grown in 9-cm-diant Petri dishes, in DMEM, containing
5% FCS, 500 U penicillin, 400 Ag gentamycin, and 100 14g streptomycin
per milliliter. Cells were transfected by using the calcium phosphate tech-
nique as previously described (Brand et al., 1988). Transfections included
eitherthe mouse RAR-yl, y2, al, or 02 expression vectors (5 Ag) and plas-
mid carrier DNA (Bluescript) to adjust the total DNA quantity to 20 Ug
per dish. F9 EC cells were grown and treated with retinoic acid (10' M)
for 24 h where indicated.
Synthesis ofPeptides, Preparation ofAntisera
and mAbs
The synthetic peptides SP15 (Al region of mouse or human RAR-yl), SP14
(F region of all mRARy isoforms), SP81 (D2 region of all human and
mouse RAR-y isoforms) and SP25 (F region of all hRAR-y isoforms) (see
Zàble1) deduced fromthe cDNA ofhuman and mouse RAR-yl were synthe-
sized in solid phase usingFmoc chemistry (model431A peptide synthesizer,
Applied Biosystems, Inc., Foster City, CA), verified by amino acid analysis
(model 420A-92OA-130A analyzer system; Applied Biosystems, Inc.) and
coupledtoovalbumin (Sigma Chemical Co., St. Louis, MO) through an ad-
ditional NH2-extraterminal cysteine residue, using the bifunctional reagent
MBS (Aldrich Chemical Co., Milwaukee, WI) .
Rabbit immunization and antisera preparation have been previously de-
scribed (Gaub et al., 1989). For mAbs preparation, 8-wk-old female Balb/c
mice were injected intraperitoneally with 100 gg of coupled antigens. 4 d
before the fusion, positive mice received a booster injection ofantigen (100
Ag), and then 10 wg (intravenous and intraperitoneal route) every day until
spleen removal. The spleen cells were fused with Sp2/O-Ag14 myeloma
cells essentially according to St. Groth and Scheidegger (1980). Culture su-
pernatants were screened by ELISAusing the unconjugated peptide as anti-
gen. Positive cultures were thentestedby immunofluorescence and Western
blotting on RAR-yl cDNA-transfected COS-1 cells as described by Lutz et
al. (1988). Hybridomas secreting antibodies recognizing specifically RAR-
yl were cloned twice on soft agar. Each hybridoma was also adapted in
serum-free medium SFRI-4 (Société française de Recherche et&Investisse-
ment, Berganton, France) . For ascite fluid production, 2 x 106 cells were
injected in pristane-primed Balb/c mice. Class and subclass determination
was performed using an Isotyping Kit (Amersham International, Amer-
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sham, UK). Both SFRI culture supernatants and ascite fluids were used as
monoclonal antibody sources.
Preparation ofWhole Cell and Nuclear Extracts
from Cultured Cellsand Mouse Embryos
Whole cell extracts (WCE) were prepared from confluent transfected cul-
tures of COS-1 cells. Cells were washed with chilled PBS, scrapped and
centrifuged. The pellet was homogenized at 4°C with a glass Dounce B
homogenizer (20 pestle strokes) in 2 vol of 10 mM Tris-HCl pH 8, contain-
ing 20 mM sodium molybdate, 0.6 M KC1, 1.5 mM EDTA, 1 mM PMSF
and protease inhibitor cocktail (PIC; leupeptin, aprotinin, pepstatin, an-
titrypsin, and chymostatin at 0.5 ug/ml each). After centrifugation for 1 h
at 105,000 g and 4°C, the supernatant was concentrated by ultrafiltration
through Centricon 30 microconcentrators (Amicon Corp., Danvers, MA).
Glycerol was added to 25% final concentration and the extracts were ali-
quoted and kept at -80°C. For the preparation of nuclear extracts (NE),
the washed cells were first lysed at 4°C with a glass Dounce B homogenizer
(15 strokes) in buffer A (20 mM Tris-HCI pH 8, 1 mM MgCIZ, 20 mM
KCI, 1 mM DTT, 0.3 mM PMSF, PIC). After centrifugation for 5 min at
1,500 g at 4°C, the crude nuclear pellet was washed twice, resuspended in
high-salt buffer B (same as buffer A but with 0.6 M KCI and 25 % glycerol)
and homogenized with Dounce B (20-30 strokes). Extraction of nuclear
proteins was performed on ice under gentle vortexing. After centrifugation
for 1 h at 105,000 g, the supernatant was concentrated by using microcon-
centrators (see above), aliquoted and frozen in liquid nitrogen.
Mouseembryos were collected at 11.5, 13.5, 14.5, and 17.5 d post-coitum
(p.c.) and nuclear extracts were prepared, according to the same protocol
except that the crude nuclear pellet was further purified in some cases by
centrifugation on a 1.7 M sucrosecushion (30 min at 1,500g) and was recov-
ered at the interphase. Proteins were quantified by the method of Bradford
(1976).
Immunoblotting
Proteins (10-70F+g) from either whole cell or nuclear extracts were fraction-
ated by SDS-PAGE (10% polyacrylamide), electrotransferred onto a
nitrocellulose (NC) filter as described (Gaub et al., 1989) and im-
munoprobed as follows. The NC filters were "blocked" in PBS-3 % nonfat
powdered milk, and then incubated for 2 h at 37°C with either rabbit poly-
clonal or mouse monoclonal antibodies at the required dilution in PBS. Af-
ter extensive washing in PBS containing 0.05% wween 20 and washing in
PBS-0.3% nonfat rowdered milk, the filters were incubated for 90 min at
20°C with either' SI-labeled Protein A or "II-labeled goat anti-mouse im-
munoglobulins (Amersham International). After extensive washing with
PBS/ween 20, the filters were dried and autoradiographed. When men-
tioned, alkaline phosphatase-coupled immunoglobulins (goatanti-rabbit or
anti-mouse immunoglobulins, Jackson ImmunoResearch, West Grove, PA)
were usedand staining wasperformed by using the NBTBCIP substrate kit
(Pierce Chemical Co., Rockford, IL).
The specificityofthe reaction waschecked by depleting theantisera from
the specific antibodies by incubation with nitrocellulose (NC) filter dotted
with the coupled peptide (20 Irg).
Gel Retardation Assay
Mobility shift assays were performed as in Garner and Revzin (1981) using
thewild-type and mutateddouble-strandedoligodeoxynucleotides (RARE-ß
and RARE-ßm, respectively) corresponding to the RARE of the RAR-ß
gene (de Thé et al., 1990) as described in Nicholson et al. (1990). Nuclear
extract, usually 5 pg protein, was incubated in a 20-Wl reaction mixture con-
taining 20 mM Tris-HCI, pH 7.5, 100 mM KCI, 1 mM MgC12, 0.1 mM
EDTA, 0.5 mM DTT, 10% glycerol, 414g poly(dI-1C), and 0.2 ng (_20,000
cpm) double-stranded [32P]5'-end-labeled synthetic RARE oligodeoxy-
nucleotide and, when requested, 1 ul ofascite fluid antibodies (diluted one-
third). Poly(dI-dC) and nuclear extract were first incubated at 4°C for 15
minbefore adding the labeledoligodeoxynucleotide. After a further 15-min
incubation on ice, the antibodies were added when requested, and the mix-
ture reaction was maintained on ice for 15 min before loading the gel. Free
DNA and DNA protein complexes were resolved on a 5% polyacrylamide
gel in 0.5x TBE (45 mM Tris-base, 45 mM boric acid, 2 mM EDTA).
Immunoprecipitations
The cell extracts (50 Ag protein) were first preabsorbed with non-immune
serum or control ascite fluid in a 1-ml final volume of 10 mM Tris-HCI,
pH 7.5, 1 mM EDTA, 0.1% Triton X-100 (buffer C) with constant agitation
536at 4°C for 1 hr. Then Protein A-Sepharose CL-4B beads (Pharmacia, Upp-
sala, Sweden) were added (100 Id of a 50% vol/vol slurry in buffer C) for
a furtherone hour incubation. The"absorbed" extract, which was recovered
in the supernatant after pelleting by centrifugation the nonrelevant pro-
tein-IgG-protein A-sepharose complexes, was incubated with 3 hl of im-
mune serum or ascite fluid for 1 h at 4°C. When using mAbs (IgGI kappa)
a further 1-h incubation witha rabbit anti-mouse IgG fraction (1.8 ltg, Jack-
sonImmunoResearch) was required as a bridge. Protein A-Sepharosebeads
were then added for 1 h at4°C. After centrifugation, the pellet was washed
four times with buffer C. Antigen-antibody complexes were eluted by incu-
bation at 100°C for 10 min in 50 ld of electrophoresis sample buffer (50
mM Tris-HCI pH 6.8, 2% SDS, 10% glycerol, 100 mM ß-mercaptoethanol,
and 0.001% bromophenol blue). Immunoblotting was then performed as de-
scribed above.
Alkaline Phosphatase Treatment
ofImmunoprecipitates
Immunoprecipitates were suspended in 100 lwl phosphatase reaction mix-
ture containing 100 mM Tris-HCI buffer (pH 9.8), 1 MM MgC12, 0.1 MM
ZnC12, PIC, and 20 U of calf intestinal alkaline phosphatase (Boehringer,
Mannheim, Germany). Sodium phosphate 10 mM was included as indi-
cated. Incubation was performed at 37°C for 3 h followed by centrifugation,
washing, addition of electrophoresis sample buffer, heating, electrophore-
sis, and immunoblotting.
Phosphate Labeling
24-h transfected COS-1 cells were first starved overnight in phosphate-
deficient DMEM, and then labeled with [32P](1 mCi/2 ml, = 2.106 cells)
for 4 h at 37°C. Cell monolayers were washed six times in ice-cold PBS
and lysed by five successive freezings (at -80°C) and thawings in buffer A.
After centrifugation at 8,000 g for 20 min at 4°C, the supernatant was sub-
jected to immunoprecipitation as described above. Proteins from the im-
mune complexeswere eluted, separatedby SDS-PAGE electrophoresis, and
electrotransferred to NC filters. The phosphorylated proteins were visual-
ized by autoradiography. Proteins were identified as mRAR-y by incubation
ofthe same filter with specific antibodies followed by an alkaline phospha-
tase-labeled second antibody as described above.
Results
(A) Preparation ofPblyclonal and
MonoclonalAntibodies against Synthetic Peptides
Specific to Human and Mouse RAR--y Isoforms
RAR-yl and y2 isoforms, which differ from each other only
in their N112-terminal A regions (Al for RAR-yl and A2
for RARy2) are highly conserved between mouse and hu-
man, both in their length which is identical, and in their
amino acid sequences which are very similar with the excep-
tion of the very COOH-terminal region (Krust et al ., 1989 ;
Kastner et al., 1990; see also Table I). The main differences
between RAR-y isoforms and RAR-a and ß isoforms are lo-
cated in the NH2-terminal A region, central D2 region, and
carboxy-terminal F region (Zelent et al., 1989; Krust et al .,
1989; Kastner et al ., 1990). Thus, to obtain specific antibod-
ies corresponding to known epitopes, we selected potential
immunogenic amino acid sequences which were either
specific to all RAR-y isoforms (regions D2 and F) or unique
to RARyl (region Al) (see Table I) . Two of these peptides
(SP15 and SP81, corresponding to regions Al and D2,
respectively) are fully conserved between humanand mouse,
whereas the two others (SP25 and SP14, corresponding both
to region F) diverge by three or four amino acids.
The four peptides were antigenic in mice and resulted in
the productionof specific hybridomas. Based on the intensity
of the reaction obtained by immunoblotting and immunopre-
cipitation, we selected one clonecorresponding to each pep-
tide: SP15 (Ablyl(Al)), SP14 (Ab2y(mF)), SP25 (Ab4y(hF)),
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Table L Amino Acid Sequence (Single Letter Code) ofthe
Synthetic Peptides Used to Generate RAR-y Antibodies
RAR-yi
RAR-y2
Peptide SP15 (Alregion) Abiy1 (A1)
mouse
human
FEHLSPSFRGLG
39 50
Peptide SP81 (D2 region) Ab5y (D2)
mouse KEEGSPDSYELS
human 172--------183
Peptide SP14 (mouse F region) Ab2y (mF), RPy(mF)
mouse SSEDEAPGGQGKRGQS
human
￿
436 -V
￿
-G 451
Peptide SP25 (human Fregion) Ab4y (hF)
mouse K-----K------A
human QPGPHPNASSEDEV
428
￿
441
RAR-yl and RAR-y2 (458 and 447 amino acids long proteins, respectively;
same length in mouse and human) are schematically represented with their six
regions designated A through F. RAR-yl and RAR-y2 differ from each other
only in their NH2-terminal A region (AI for RAR-yl and A2 for RAR-y2).
The amino acid sequence (single letter code) of the synthetic peptides used to
generate RAR-y antibodies are represented. The numbers flanking the peptide
sequences correspond to the portion of the respective amino acid residues in
the sequence of RAR-y isoforms. Amino acids differing between mouse and
human RAR-y are indicated.
and SP81 (AMy(D2)). Each clone recognized specifically
its cognate, but not other peptides, as checked by ELISA
(data not shown) . All four antibodies were identified as IgGI
kappa. Peptides SP14, SP15, and SP25 resulted also in the
production of polyclonal antibodies in rabbits, but only the
polyclonal antibody preparation against SP14 (RPy(mF)),
which gave the strongest reaction was further studied here.
All these antisera were tested by immunocytochemistry for
their ability to reveal the proteins generated by transfecting
the expression vector RARyl in COS-1 cells. As previously
described for RARa and RAR-ß (Gaub et al., 1989), an in-
tense nuclear staining was observed when RAR-11-transfected
cells were treated with RPy (mF) (Fig. 1 A), Ablyl (Al)
(Fig. 1 D), Ab2y (mF) (Fig. 1 H), and Ab5y (D2) (Fig. 1
I). No staining was observed when the cells were treated
with either nonreactive serum (Fig. 1 C) or nonreactive as-
cites (Fig. 1 G), or transfected with either mRAR-al (Fig.
1 E) or mRAR-ß2 (Fig. 1 F).
(B) Specific Detection ofCloned Human
and Mouse RAR-y Proteins by Immunoblotting,
Immunoprecipitation, and Gel ShiftAssay
(i) Immunoblotting. The monoclonal antibodies as well as
the rabbit polyclonal antisera were tested for their ability to
62 90 156 202 422 458
Al B C DijD2 D3 E F
51 79 145 191 411 447
A2 B C Dt D2 D3 E FFigure 1. Immunocytochemistry of COS-1 cells transfected with
mRAR-yl using either polyclonal or monoclonal anti-RAR-,yl an-
tibodies . (A) RPy(mF) ; (D) Ablyl(Al) ; (H) Ab2y(mF) ; (I)
Ab5y(D2) . Transfected cells were fixed, permeabilized and in-
cubated with the specific antibodies as previously described (Gaub
et al ., 1989) . Then, Texas Red-labeled second antibodies were used
as recommended by the manufacturer (Amersham International,
Amersham, UK) . Controls were performed with preimmune non-
reactive serum (NRS, C) or nonreactive ascite fluid (NRA, G) . Im-
munofluorescence was also performed with Ablyl(Al) on mRAR-
al (E) and mRAR-ß2 (F) transfected-COS-1 cells . Nuclei were
stained with Hoechst reagent (B) . Intense nuclear staining was ob-
served with all antibodies (A, D, H, and 1) . Bar, 25 /,m . x400.
reveal specifically on Western blots the cloned mouse or hu-
man RAR-y proteins produced by transfected COS-1 cells
(see Materials and Methods) . Whole cell extracts (WCE) of
COS-1 cells transfected with vectors expressing either the
human or mouseRAR-yl isoform were fractionated by SDS-
PAGE and electroblotted onto nitrocellulose (NC) filters .
After incubation of the filters with the specific monoclonal
antibodies or the rabbit antisera, antibody-antigen com-
plexes were revealed by using 125I-anti-mouse immunoglob-
ulins or 1251-Protein A respectively (Fig . 2 A) .
In extracts of COS-1 cells transfected with mRAR-yl ex-
pression vector, the mAbs Ablyl(AI), Ab5y(D2), and
Ab2y(mF), as well as the SP14 rabbit antiserum RPy(mF),
resulted in a specific, strongly labeled signal with an appar-
ent molecular mass of =51 kD (Fig . 2 A, lanes 2, 5, 8, and
14), which is in excellent agreement with the cDNAdeduced
molecular mass of the mRAR-yl protein (M, = 50,347 ;
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Krust et al ., 1989) . It must be noted that a specific additional
signal with a lower apparent molecular mass and of variable
intensity depending on the cell extract was detected with the
monoclonal Ablyl(Al) (Fig . 2 A, lane 2 ; see also Fig . 3 A,
lane 7) . Similarly, with monoclonal Ab2y(mF) and poly-
clonal RPy(mF), a specific additional minor signal with a
higher apparent molecular weight (and variable intensity)
was seen (Fig . 2 A, lanes 8 and 14 ; see also Fig . 3 A, lanes
1 and 13) . No labeling was detectable with the mAb
Ab4y(hF) (data not shown) . In hRAR-yl-transfected COS-1
cells extracts, a similar specific 51-kD signal was also re-
vealed by Western blotting with Ablyl(Al), Ab2y(mF), and
Ab5y(D2) (data not shown), as well as withAb4-yf) (Fig .
2 A, lane 11) . However, the RPy(mF) antiserum did not
recognize the human cloned receptor (data not shown) .
When the ascite fluids and the antisera were depleted from
the specific antibodies as described in Materials and Meth-
ods, all of the above specific signals were no longer seen
(Fig . 2 A, lanes 3, 6, 9, 12, and 15) . Similar competition ex-
periments using ovalbumin alone did not affect the intensity
of the specific signals (data not shown) . No specific labeling
was observed on Western blots performed with extracts of
untransfected COS-1 cells (Fig . 2 A, lanes 1, 4, 7, 10, and
13), suggesting a very low level of expression of RAR-yl
protein in these cells . Furthermore, no cross-reactions were
seen with the same antibodies using extracts from COS-1
cells* transfected with either RAR-al or RAR-02, (data not
shown), as confirmed by immunocytochemistry (Fig . 1, E
and F), indicating that the present antibodies are specific
for the RAR-yl protein . However, as expected, Ab5y(D2),
Ab2y(mF), and RPy(mF) reacted also specifically with ex-
tracts from mRAR-y2 transfected COS-1 cells and revealed
a protein with an apparent molecular weight of =48 kD (Fig .
2 A, lanes 19, 21, and 23) . In some instances, and for un-
known reasons, this 48-kD species was strongly decreased
in favor of a specifically reacting protein with an apparent
molecular weight of=45 kD (see for instance Fig . 2 B, lanes
16 and 20; and Fig . 3 C, lanes 2 and 7) . In contrast, the
mRAR-y2 protein present in these extracts was not recog-
nized by Ablyl(Al), in agreement with the presence of a
differentA region (A2) in the mRAR-y2 isoform (see above)
(Fig. 2 A, lane 17) .
These results demonstrate that the mAbs Ab2y(mF) and
Ab5y(D2) recognize specifically the corresponding epitopes
present in both human andmouse RAR-y proteins, whereas
the Ab4y(hF) antibody recognizes specifically the corre-
sponding epitope present in human RAR-y isoforms. Con-
versely, the polyclonal antiserum RPy(mF) recognizes only
the corresponding epitope present in mouse RAR-y iso-
forms . These results show also that the monoclonal antibody
Ablyl(Al) reacts specifically with the corresponding epitope
which is present in human and mouse RAR-yl isoform, but
not in human and mouse RAR-y2 isoform .
(ii) Immunoprecipitation . The three mAbs (Ablyl(Al),
Ab2y(mF), and Ab5y(D2)) as well as RPy(mF) also spe-
cifically immunoprecipitated mRAR-yl protein from whole
cell extracts of mRAR-yl-transfected COS-1 cells, as shown
by subsequent Western blotting (Fig . 2 B, lanes 9-12) . As ex-
pected (see above), no specific signal was seenwhen extracts
from mRAR-y2-transfected cells were immunoprecipitated
with Ablyl(Al) (Fig . 2 B, lane 17), whereas signals were ob-
served when using the same extracts and either Ab5y(D2)
538Figure 2 . (A) Characterization of
monoclonal and polyclonal anti-
bodies by Western blotting.COS-1
cells extracts were either from
control untransfected COS-1 cells
(lanes 1, 4, 7, 10, and13)or from
COS-1 cells transfected with
mRARy-1 (lanes 2, 3, 5, 6, 8, 9,
14, 15, 16, 18, 20, and 22),
hRAR-yl (lanes 11 and 12) or
mRAR-y2 (lanes 17, 19, 21, and
23) expression vectors. The ex-
tracts were fractionated by SDS-
PAGE, electrotransferred onto
NC filters and then immunoprobed
with the mAbs Ablyl(Al) (lanes
1-3, 16, and 17), Ab5y(D2)
(lanes 4-6, 18, and 19), Ab2y-
(mF) (lanes 7-9, 20, and 21),
Ab4y(hF) (lanes 10-12) or the
rabbitpolyclonal antibodies RPy-
(mF) (lanes 13-15, 22, and 23),
without (lanes 1, 2, 4, 5, 7, 8, 10,
11, 13, 14, and 16-23) or with
previous antibody depletion (lanes
3, 6, 9, 12, and 15) as described
in Materials and Methods. The
position of the prestained molec-
ular weight standards (Bethesda
Research Laboratories, Gaithers-
burg, MD) is indicated in kilo-
daltons. (B) Characterization of
monoclonal and polyclonal an-
tibodies by immunoprecipitation .
Extracts from either pSG5 (lanes
2-7), mRAR-yl (lanes 9-14), or
mRAR-y2 (lanes 17-19) trans-
fected COS-1 cells were immuno-
precipitated (as described in Ma-
terials andMethods) with the fol-
lowing antibodies: RPy(mF),
lanes4and9 ; Ably1(Al), lanes 5,
10, and 17, Ab5y(D2), lanes 6, 11,
and 18; Ab2y(mf, lanes 7, 12,
and 19; nonreactive rabbit serum
(NRS), lanes 2 and 13 ; non-reac-
tive ascite (NRA), lanes 3 and
14. Antigen-antibody complexes
bound to Protein A Sepharose
beads were eluted, fractionated
by SDS-PAGE, and electrotrans-
ferred to NC filters . The immu-
noprecipitated material was im-
munoprobed by incubation of the
filters with RPy(mF) and'"-Pro-
tein A. As positive controls, ex-
tracts (10 hg protein) ofmRAR-
yl (COS-yl, lanes 1, 8, 15, and
21) or mRAR-y2, lanes 16 and
20) transfected COS-1 cells were
directly loaded on the gel without prior immunoprecipitation, and then immunoprobed . (C) Characterization ofmAbs by their effects on
the DNA-protein complexes formed in vitro with the RARE of the RAR-ß2 promoter using gel retardation/shift assay. Gel retardation
reactions were carried out with5 l~g of extracts from COS-1 cells transfected with either mRAR-yl (lanes 1-7), mRAR-al (lanes 8-13)
ormRAR-ß2 (lanes 1417)expression vectors . Arrow1 indicates the specific complexesformed with theRARE-flprobe . Arrow2 indicates
the shifted complex formed in the presence of the monoclonal antibodies : Ablyl(Al), lane 3; AWy(mf , lanes 4, 10 and 16 ; Ab5y(D2),
lane 5; Ab9af), lanes 6 and 11 ; Aó702 (Al) : lanes 7, 12 and 17 ; Non Reactive Ascite (NRA), lane 13. The monoclonal antibodies
Ab9a(hF) and Ab7ß2(Al) have been raised against synthetic peptides corresponding to amino acid stretches ofthe F region of RAR-al,
and of the Al region of RAR02, respectively (manuscripts in preparation) .
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539Figure 3 . Characterization of RAR--y isoforms in F9 cells and mouse embryos. (A) Immunoblotting . Nuclear extracts (70 Fig protein) of
F9 cells (lanes 1-15)andmouseembryos (lanes 16-22) were fractionated by SDS-PAGE, electrotransferred toNC filters andimmunoprobed
with : RP7(mF), lanes 1-3, lá-20; Ablyl(Al), lanes 7-9; Ab5 ,y(D2), lanes 10-12 ; Ab2 ,y(mF), lanes 13-15. The incubations were also
performed with antibody-depleted RPy(mF) lanes 4-6, 21 and 22). F9 cells were tested either with (lanes 3, 6, 9, 12, and 15) or without
(lanes 2, S, 8, 11, and 14) a 24-h retinoic acid treatment . Mouseembryoswere tested at 11.5 d (lane 17), 13.5 d(lanes 18 and 22), 14.5 d
(lane 19) and 17.5 d (lane 20) . As positive controls, extracts of mRAR--yl-transfected COS-1 cells (COS-yl) were run in parallel (lanes
1, 4, 7,109 13, 16, and 21) . (B) Characterization of RAR-y in mouse embryos by immunoprecipitation. Nuclear extracts (1 mg protein)
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540or Ab2y(mF) (Fig. 2 B, lanes 18 and 19) . Also, as expected
RPy(mF) did not immunoprecipitate hRARyl from extracts
of hRAR-yl-transfected cells, whereas Ab4y(hF) did it but
with a lower efficiency than Ablyl(Al), Ab5y(D2), or
Ab2y(mF) (data not shown). In all cases the signals were
specific, since they were not observed when immunoprecipi-
tation was performed with preimmune nonreactive serum
(NRS) or a control nonreactive ascite fluid (NRA) (Fig. 2 B,
lanes 13 and 14) or with cell extracts transfected with the pa-
rental expression vector pSG5 (Fig. 2 B, lanes 4-7). Further-
more, the signals disappeared specifically when the Western
blotting step was performed with an antibody-depleted ascite
fluidor serum (data not shown). A minor signal correspond-
ing to the immunoprecipitatiog rabbit immunoglobulins was
occasionally revealed (data not shown, and Fig. 2 B, lane 4) .
(iii) Gel Shift Assay. To confirm the specificity of the
present antibodies for the RAR-y isoforms, gel shift/retarda-
tion assays were performed using a "P-labeled oligodeoxy-
nucleotide (RARE-0, see Materials and Methods) contain-
ing the RA response element (RARE) of the RAR-02
promoter (de Thd et al ., 1990; Sucov et al., 1990; Nicholson
et al ., 1990 ; Zelent et al., 1991; Vasios et al., 1991) . With
extracts ofCOS-1 cellstransfected with mRAR-yl, a specific
complex was obtained (arrow 1 in Fig. 2 C, lane 2) which
disappeared when the oligonucleotide was mutated (RARE-
0m, see Materials and Methods) (Fig. 2 C, lane 1) . The
above complex was shifted to a more slowly migrating spe-
cies (arrow 2 in Fig. 2 C) after the addition of the monoclo-
nal antibodies Ablyl(Al) and Ab2y(mF) (Fig. 2 C, lanes 3
and 4) . However, Ab5y(D2) was less effective in inducing
such a shift (Fig. 2 C, lane 5). Similarly, the addition of ei-
ther Ablyl(Al) (see Nicholson et al ., 1990) or Ab4y(hF)
(see Vasios et al., 1991) resulted in a shift of the probe-re-
ceptor complex obtained with extracts of hRAR-yl-trans-
fected cells. As expected, the probe-receptor complexes
formed with mRAR-y2-transfected cellswere clearly shifted
with Ab2y(mF) and to a less extent with Ab5y(D2), whereas
no shift was observed with Ablyl(Al) (data not shown) . In
contrast, mAbs specifically directed against either mRAR-
al [Ab9a(hF)] or mRAR-02 [Ab702(Al)] did not induce any
shiftof the probe-RAR complex obtained with COS-1 cells
expressing mRAR-yl (Fig. 2 C, lanes 6and 7). Furthermore
none of the mAbs raised against mRAR-,y1 led to a shift of
the probe-RAR complex obtained with COS-1 cells express-
ing either mRAR-al or mRAR-02 (Fig. 2 C, lanes 10 and
16, and data not shown), thus confirming that they are spe-
cific for RAR-y isoforms.
(C) Detection ofRAR-y Isoforms in F9 Embryonal
Carcinoma Cells and Mouse Embryos
We investigated whether all of the RAR-,y antibodies charac-
terized above could detect the presence of RAR-y isoforms
in mouse F9 embryonal carcinoma cells and mouse embryos.
mRAR-yl and mRAR-y2 messenger RNAs have indeed been
found in F9 cellsand in mouse embryos at various stages of
development (Zelent et al., 1989; Kastner et al., 1990). The
possible presence of mRAR-y isoforms was first investigated
by Western blotting using nuclear extracts from either F9
cells (treated or not with RA) or mouse embryos. No signal
was detected when the mAbs Ablyl(Al), Ab5y(D2), and
Ab2y(mF) were used (Fig. 3 A, lanes 7-15 and data not
shown). However, with the RPy(mF) antiserum a signal cor-
responding to a protein with an apparent molecular mass of
85 kD was detected, instead of the expected 51-kD cloned
RAR-yl molecule (Fig. 3 A, lanes 2, 3, and 17-20, arrow).
This signal, which was specific since it disappeared after an-
tibody depletion of the antiserum (Fig. 3 A, lanes 5, 6, and
22), may correspond to a 85-kD protein bearing a similar
cross-reacting epitope(s). The lack of signals with the mono-
clonal antibodies suggested that the epitopes recognized by
these antibodies could be modified posttranslationally in F9
cells and mouse embryos, and/or that the RAR-y proteins
may be synthesized in amounts too low to be detectable by
Western blotting.
We thus performed immunoprecipitation experiments
using the same cell and embryo extracts. A protein with the
expected RAR-yl molecular mass (51 kD) was revealed on
Western blots using RPy(mF) after immunoprecipitation of
nuclear extracts of mouse embryos (14 .5 d p.c.) with either
Ablyl(Al) (Fig. 3 B, lane 3), Ab2y(mF) (Fig. 3 B, lane 4),
Ab5y(D2) (Fig. 3 B, lane 5) . Note that, to be seen, these
signals required that -1 mg ofnuclear proteins was immuno-
precipitated. However, they were specific since they disap-
peared when the NC filter was revealed with antibody-de-
pleted RPy(mF) (data not shown). Using F9 cell extracts,
two signals (corresponding either to a molecular mass simi-
lar to that of RAR-y2 [N48 kD] or to a lowerone [ti42 kD],
were specifically immunoprecipitated from 1 mg of nuclear
proteins with Ab2y(mF) (Fig. 3 C, lane 4), Ab5y(D2) (Fig.
3 C, lane 5). However no signal was seen when F9 cell ex-
tracts were immunoprecipitated with Ablyl(Al) (Fig. 3 C,
lane 3) . The same pattern was observed whether the F9 cells
were treated or not for 24 h with RA (data not shown).
Moreover, the obtained signal was not increased when the
three mAbs were added together (data not shown) .
(D) Phosphorylation ofMouse RAR-yl
Multiple electrophoretic species were seen for the mRAR-y1
protein made in COS-1 cells, and revealed with antibodies
Ablyl(Al), AWy(mF), and RPy(mF) (Fig. 2 A and 3 A),
which suggests the possible occurrence of post-translational
modifications. Protein phosphorylation often alters mobility
of 14.5-d mouse embryos were immunoprecipitated with the mAbs Abl-yl(Al) (lane 3), Ab2y(mF) (lane 4), or Ab5,y(D2) (lane 5). Anti-
gen-antibody complexes bound to Protein A Sepharose beads were eluted, fractionated by SDS-PAGE, and electrotransferred to NC filters.
The immunoprecipitated mRAR-y proteins were immunoprobed by incubation of the filters with RPy(mF) and [12sí]Protein A. As posi-
tive controls, extracts (10 )Ag protein) of mRAR-,y I (lanes 1 and 6) and mRAR-y2 (lanes 2 and 7) transfected COS-1 cells were directly
loaded on the gel without priorimmunoprecipitation and then immunoprobed. The arrow indicates the position of mRAR-y 1. (C) Charac-
terizationof RAR-y in undifferentiated F9 cells by immunoprecipitation. Nuclear extracts (1 mg protein) of F9 cells were immunoprecipi-
tated with the mAbs Ablyl(Al) (lane 3), Ab2y(mF) (lane 4), and Ab5y(D2) (lane 5). The immunoprecipitated RAR-y proteins were
immunoprobed as described in B with RPy(mF). Extracts (10 leg protein) of mRAR-yl (lanes 1 and 6) or mRAR-y2- (lanes 2 and 7)
transfected COS-1 cells were directly loaded on the gel, as positive controls. The position of the mRAR-yl and mRAR-y2 controls are
indicated by thick and thin arrows respectively.
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541during SDS-PAGE . Thus Ab2y(mF) immunoprecipitates of
mRAR-yl-transfected COS-1 cell extracts were treated with
calf intestinal alkaline phosphatase (CIP) in the presence or
absenceof sodium phosphate, aphosphataseinhibitor. In the
absenceof inhibitor, CIPtreatmentincreased themobility of
mRAR-yl, as compared to the untreated controls (Fig . 4,
lanes4and5) . This effectwasno longer visible afterphospha-
tase treatment in the presence of inhibitor (Fig . 4, lane 6) .
To confirmthese results, we examined thephosphorylation
state ofRAR-yl and the effect of retinoic acid treatment on
phosphorylation . mRAR-yl-transfectedCOS-1 cells were la-
beled with [3zP]orthophosphate in the presence or absence
ofRA (10-7 M) and the RAR-yl proteins were immunopre-
cipitated with the specific mAbs Ab2y(mF) . A phos-
phorylated protein with an apparent molecular mass of 51
kD and corresponding to RAR-yl (as determined by immu-
noblotting on the same NC filters, using RPy(mF) andalka-
line phosphatase conjugated goat anti-rabbit antibody) was
detected (Fig . 5 A, lanes 2, 3, 6, and 7) . No variation in the
phosphorylationintensitywas seen after 4 h ofRA treatment
(Fig . 5 A, compare lanes 6and 7) . No phosphorylated pro-
tein was detectable in COS-1 cells which had been trans-
fected with the parental expression vector pSG5 (Fig . 5 A,
lanes 4, 5, 8, and 9) . These results indicate that the RAR-yl
protein can exist in a phosphorylated state .
To investigate which domain(s) of RAR-yl are phos-
phorylated, we constructed three expression vectors encod-
ing chimeric proteins, Gal4-RAR-yl (A/B), Ga14-RAR-yl
(EF), and Ga14-RARyl (DEF) in which the GA14 (1-147)
DNA binding domain is fused with either the A/B, EF, or
DEFregions ofmRAR-yl, respectively. Thesechimeric pro-
teins also contained the F region of the estrogen receptor
(ER) against which immunoprecipitating monoclonal anti-
bodies (AbF3) have been raised (Rochette-Egly et al ., 1990).
COS-1 cells were transfected, labeled with [3zP] and the
chimeric proteins were immunoprecipitated with the mAb
AM . The expected chimeric proteins were revealed after
electrophoresis by immunoblotting (Fig . 5 B, lanes 1, 3, 5,
and 7, arrows ; Ga14-Exon(8) is a chimeric protein that con-
tains the Ga14 DNA binding domain fusedto theER region
F; see Webster et al ., 1989) . Autoradiography of the same
NC filters revealed that the proteins encoded by the Ga14-
RAR-yl(A/B) and Ga14-RAR-yl(DEF) expression vectors,
were phosphorylated (Fig. 5 B, lanes 4 and 8) . The phos-
phorylation ofGAIA-RAR-yl (DEF)wasnot affected byRA
treatment, (data not shown) . However, the protein encoded
by the Gal4-RAR-yl(EF) expression vector was not labeled
either in the presence or absence of RA (Fig . 5 B, lane 6),
suggesting that the D region, but not the EF region, might
contain phosphorylation site(s) . No [3zP] labeling was as-
sociated with the Ga14-Exon(8) protein indicating that the
Ga14-DNA binding domain as well as theF region ofthe es-
trogen receptor were not phosphorylated underthesecondi-
tions (Fig . 5 B, lane 2) .
Discussion
In this study, we have described the production, character-
ization, and use of antipeptide antibodies that are directed
against RAR-y isoforms . Four monoclonal antibodies di-
rected against the Al region (Ablyl(Al)), the D2 region
(Ab5-y(D2)), and the F region (Ab2y(mF) and Ab4yf))
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Figure 4 . Alkaline phosphatase treatment increases the elec-
trophoretic mobility of mRAR-yl protein . Extracts of mRAR-yl
transfected COS-1 cells were immunoprecipitated using the
Ab2y(mF) mAbs (lanes 3-6) and the antigen-antibody complexes
immobilized on Protein A-Sepharose beads were incubated with
(lanes 5and 6) or without (lane 4) calf intestinal alkaline phospha-
tase (CIP) in the absence (lanes 4 and 5) or presence (lane 6) of
10 mM sodium phosphate . The untreated (lane 3) and incubated
(lanes 4-6) immunoprecipitates were then solubilized, subjected to
electrophoresis, and electrotransferred to NC filters. The mRAR-
,yl protein was identified by incubation ofthe filter withRPy (mF)
and [125J]ProteinA. In parallel, extracts of COS-1 cells transfected
with mRAR-y 1 (lanes 2and 7) ormRAR-y2 (lanes I and 8) expres-
sion vectors were run without prior immunoprecipitation .
and one rabbit polyclonal antiserum directed against the
mouse Fregion (RPy(mF)), were obtained andwere specific
for the predominant RAR-yl isoform . All these antibodies
immunoprecipitate and recognize specifically by immuno-
blotting a 51-kD protein in nuclear extracts of RAR-yl-
transfected COS-1 cells . This apparent molecularmass is as
predicted from the RAR-yl cDNA sequence (Krust et al .,
1989) . This 51-kD protein has a nuclear localization and is
absent from cytosolic extracts as confirmed by immunostain-
ingofRAR-yl transfected cells . Additionally, inDNAbind-
ing assays, theantibodies specifically retard themigrationof
the complexobtained between extracts of transfected COS-1
cells and theRA response elementof the RAR-ß2 promoter
(RARE-0) . These results indicate that our antipeptide anti-
bodies specifically recognize the corresponding epitope of
RAR-yl protein produced in cells transfected with expres-
sion vectors containing the RAR-71 cDNAs . The antibodies
542Figure 5. Phosphorylation of mRARyl . (A) COS-1 cells trans-
fected with either pSG5 (lanes 4, 5, 8, and 9) ormRAR-yl expres-
sion vector (lanes 2, 3, 6, and 7) were labeled with [3zP] in the
presence or absence of retinoic acid (see Materials and Methods)
and were analyzed by immunoprecipitation with Ab2y(mF) . After
electrophoresis and electrotransfer toNC filters the immunoprecip-
itated phosphorylated proteins were visualized by autoradiography
(lanes 6-9) and identified by incubation of the sameNC filter with
RPy(mF) followed by alkaline phosphatase-labeled antirabbit anti-
bodies (lanes 2-5) . Extracts (10 Fig protein) of mRAR-yl trans-
fected COS-1 cells were run and electroblotted in parallel as a con-
trol (lane 1) . (B) COS-1 cells were transfected with the following
chimeric expression vectors : GAL4-Exon(8) (lanes 1 and 2),
GAL4-RAR-yl(A/B) (lanes 3 and 4), GAL4-RAR-yl(EF) (lanes 5
and 6), GAL4-RAR-,yl(DEF) (lanes land 8) . After labeling with
[3zP], the extracts were immunoprecipitated with the mAbs AbF3
(see Materials andMethods) . The immunoprecipitates were eluted,
subjected to electrophoresis and electrotransferred to NC filters .
The phosphoproteins were analyzed by autoradiography (lanes 2,
4, 6, and 8) and identified by incubation of the sameNC filter with
AbF3 and revelation with alkaline phosphatase-labeled anti-mouse
antibodies (lanes 1, 3, 5, and 7) . The arrows indicate the position
ofthe proteins produced by the chimeric expression vectors . Aster-
isks indicate contaminating immunoglobulins .
Rochette-Egly et al . Retinoic Acid Receptor y: Antibodies and Phosphorylation
￿
543
directed against the D2 (Ab5y(D2)) and F(Ab2y(mF),
Ab4y(hF) and RPy(mF)) regions recognized also theRAR
y2 isoform, whereas Ablyl(Al) did not, in agreement with
the presence of a different A region (A2 in the RARy2
isoform) .
The three mAbs Ablyl(Al), Ab2y(mF), and Ab5y(D2)
recognized either human or mouse RAR-y proteins . How-
ever, the polyclonal rabbit antibodies RPy(mF) even though
it was raised against the same peptide SP14 (mouse F region)
that yielded the monoclonal Ab2y(mF), recognized spe-
cifically the mouse RARy isoforms and not their human
counterparts . Conversely, Ab4y(hF) was specific for human
RAR-y proteins, although the sequence of the peptide SP25
used as antigen (human F region) contains amino acid
residues overlapping the sequence of the mouse counterpart
(SP14) .
These antibodies allowed the detection of endogenous
RAR-y isoforms in mouse embryos and F9 embryonal carci-
noma cells nuclear extracts . In both cases mRAR-y proteins
were not detectable by immunoblotting, but could be immu-
noprecipitated from large amounts (1 mg protein) of nuclear
extracts . Thus, the endogenous mRAR-y isoforms appear to
be present in low amounts in mouse embryos and F9 cells .
A species corresponding to the mRAR-yl isoform (51 kD)
was specifically immunoprecipitated from mouse embryos
nuclear extracts with monoclonal antibodies directed against
either the Al, D2, orF regions . In F9 cells nuclear extracts,
one RAR-y species with a molecular weight corresponding
to that of the RAR-y2 isoform (48 kD) was immunoprecipi-
tated as well as a second species with a lower molecular
weight (42 W) . As previously reported for mRAR-y tran-
scripts (Kastner et al., 1990) the intensity of these signals
was not affected by RA treatment ofF9 cells. Since these spe-
cies were specifically immunoprecipitated with Ab2y(mF)
and AM-y(D2), but not with Ablyl(Al), they may cor-
respond to the isoform mRAR-y2 and to a proteolytic prod-
uct of this isoform . Alternatively, the lower species may cor-
respond to the isoforms mRAR-y5 and/or mRAR-y6, even
though the corresponding mRNAs appear to be present in
very low amounts in F9 cells (Kastner et al ., 1990) . Further
studies with specific antibodies directed against the mRAR-
y2 isoform are required to investigate these possibilities.
The present antibodies allowed us to demonstrate that
RAR-yl is modified posttranslationally . mRAR-yl appears
to be a phosphoprotein as are steroid hormone receptors (for
review see Aurichhio, 1989) . In vitro phosphatase treatment
converted mRAR-yl to a faster electrophoretic form as pre-
viously described for the glucocorticoid and progesterone
receptors (Hoeck et al., 1989 ; Denner et al ., 1990a), or for
other transcription factors such as Ga14 (Mylin et al ., 1989),
the heat shock transcription factor (Sorger and Pelham,
1988), the adenovirus EIA protein (Dumont et al ., 1989 ;
Smith et al ., 1989), the octamer transcription factor (Tanaka
and Herr, 1990), the cAMP-responsive transcription factor
CREB (Gonzalez et al ., 1991) and Fos (Ofir et al ., 1990) .
Furthermore mRAR-yl could be labeled in vivo with ["P],
both in the absence and presence ofRA . With the help ofchi-
meric constructions in which the Ga14(1-147) DNA binding
domain was fused with the A/B, EF, or DEF regions of
mRAR-yl, we found that the A/B and most probably the D
regions ofRAR-yl contain phosphorylation sites . However,
since in the latter case theprotein encoded by the Gal4-RAR-TableIL Protein Kinase PhosphorylationSite Motifs
Possible phosphorylation
Protein kinases
￿
recognition motifs
In the AIB domain
cAMP-dependent kinase
￿
34R G _S*
Casein kinase I
￿
40E ML_S*
57E MA_S*
64E TQ_S*
Casein kinase II
￿
1ß_S*GYP
67_9*T SS
69S* S EE
Proline-dependent kinase
￿
36S*_P
43S*_P
77S*_P
79S* P
In the D domain
Casein kinase I
￿
173E EG_S*
Casein kinase II
￿
1769* PDS
Glycogen synthase kinase 3
￿
179S*YELS
Proline-dependent kinase
￿
176S* _P
1835* P
The localization of the possible phosphorylation recognition motifs for a num-
ber of protein kinases in the amino acid sequence of A/B and D regions of
RAR-yI (see Kempand Pearson, 1990) is represented. The phosphate acceptor
serines are indicated with an asterisk. Where the specificity determinants for
a protein kinase are known, determinant residues are underlined. Numbers in-
dicate the position of the first amino acid in the putative recognition motif.
yl(DEF) expression vector and not that encoded by Ga14-
RAR-y(EF) was phosphorylated, we cannot exclude the pos-
sibility that the EF region could in fact be phosphorylated
in a D domain-dependent manner. Whether the DNA bind-
ing domain (region C) may also be phosphorylated remains
to be investigated.
Although the precise location of the phosphorylated resi-
dues of RAR-yl is unknown, we note that both the A/B and
D regions correspond to the portion of the protein that con-
tains most of serine residues which are in consensus se-
quences of knownkinases, such as cAMP-dependent kinase
(RXSX), proline directed kinase (XSPX ), casein kinases I
(EXX§) and II (§XXS, §XXE, AXXP), and glycogen syn-
thase kinase 3 (X§XXXSX) (see Kemp and Pearson, 1990
and Table II) . Phosphorylation in the A/B domain has been
also reported for the glucocorticoid (Hoeck and Groner,
1990; Bodwell et al., 1991) and thyroid hormone (Goldberg
et al ., 1988; Glineur et al., 1989) receptors. Moreover phos-
phorylation of serine residues has been observed in both the
NHZ-terminal region and the central D region (between the
DNA and hormone binding domains) of the progesterone
receptor (Denver et al., 1990a). However, phosphorylation
ofRARyl occurs irrespective of the presence of RA, in con-
trastto whathas been found for the progesterone, glucocorti-
coid, and 1,25-dihydroxyvitamin D3 receptors whose phos-
phorylation increases in the presence of hormone (Denver
et al., 1990b; Bodwell et al., 1991; Brown and Deluca,
1990). The possible effect of phosphorylation on the func-
tion of RARy is unknown. In this respect, we note that the
role ofphosphorylation on the function of other members of
the nuclear receptor superfamily (see above for references)
remains also to be discovered. Phosphorylation couldaffect
the tertiary structure ofRAR-y, which may result in the "un-
masking" of a transcriptional activation function, as it was
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recently proposed in the case of the transcription factor
CREB (Gonzalez et al., 1991) . Phosphorylation may also
control the rate of nuclear transport of RAR-y as it was
shown in the case ofSV40 T antigen whose nuclear localiza-
tion signal (NLS) is flanked by a casein kinase II site (Rihs
et al., 1991). We note in this respect that the D region of
RAR-y contains casein kinase II sites as well as stretches of
basic amino acids which may correspond to NLS. Site
directed mutagenesis of the potential phosphorylation sites
in RAR-y is obviously required to investigate this and other
possibilities.
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